The latest price target for Exagen (NASDAQ:XGN) was reported by Cantor Fitzgerald on May 14, 2024. The analyst firm set a price target for $7.00 expecting XGN to rise to within 12 months (a possible 140.55% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Exagen (NASDAQ:XGN) was provided by Cantor Fitzgerald, and Exagen maintained their overweight rating.

There is no last upgrade for Exagen

There is no last downgrade for Exagen.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.

While ratings are subjective and will change, the latest Exagen (XGN) rating was a maintained with a price target of $5.00 to $7.00. The current price Exagen (XGN) is trading at is $2.91, which is out of the analyst’s predicted range.